P&U's Fred Hassan: The Virtue of "Been There, Done That"
P&U managed to turn itself around following the near-disaster of its merger between Swedish Pharmacia and American Upjohn, with much of the credit due to its CEO and the subject of this interview, Fred Hassan. Hassan consolidated its autonomous research and marketing centers and focused development and marketing efforts on a few heretofore under-resourced drugs. He had the advantage of being new to the job, brought in to salvage an already bad situation. His experience with previous deals at American Home certainly helped. And he argues his consolidation experience will help with Monsanto, too--though now he's an insider trying to manage a merger of equals. But the central value of the P&U and P&U/Monsanto deal is the same: create a vastly increased marketing force to turbocharge the launch of the company's new products.
You may also be interested in...
Cultural transformation was the main topic of Warburg Pincus managing director Fred Hassan’s keynote talk at the Therapeutic Area Partnerships meeting on Nov. 19, where the audience also drew on the investor’s extensive track record leading some of pharma’s most successful turnarounds.
CEO Fred Hassan faults decentralization and financial over-management for much of Schering's trouble--including its inability to fix its manufacturing problems, its lack of oversight over its sales force, and its inadequate response to the competitive threat from Roche. Cutting costs further--as some analysts looking for short-term earnings growth would like to see--won't help. Instead, Hassan's investing-particularly in marketing-oriented clinical studies.
Starting out with a CNS research program left behind in the restructuring that created Pharmacia Corp., Newron Pharmaceuticals SPA has launched a program to develop ion channel-targeted drugs for epilepsy, neuropathic pain, Parkinson's disease and other neurodegenerative disorders.